Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates

Am J Clin Pathol. 2022 Feb 3;157(2):257-265. doi: 10.1093/ajcp/aqab115.

Abstract

Objectives: Cefiderocol is a novel siderophore cephalosporin with in vitro activity against multidrug-resistant (MDR), gram-negative bacteria and intrinsic structural stability to all classes of carbapenemases. We sought to identify gene variants that could affect the mechanism of action (MOA) of cefiderocol.

Methods: We report a case of bacteremia in a liver transplant candidate with a strain of carbapenem-resistant Escherichia coli that was found to be resistant to cefiderocol despite no prior treatment with this antimicrobial agent. Using whole-genome sequencing, we characterized the genomic content of this E coli isolate and assessed for genetic variants between related strains that were found to be cefiderocol susceptible.

Results: We identified several variants in genes with the potential to affect the mechanism of action of cefiderocol.

Conclusions: The cefiderocol resistance in the E coli isolate identified in this study is likely due to mutations in the cirA gene, an iron transporter gene.

Keywords: AP infectious disease; CP microbiology; Molecular diagnostics.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Cefiderocol
  • Cephalosporins / pharmacology
  • Escherichia coli* / genetics
  • Genomics
  • Humans
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Cephalosporins